You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Managing the Patient With DME: What's on the Horizon?

  • Authors: Jean-François Korobelnik, MD, PhD; Anat Loewenstein, MD, MHA; David M. Brown, MD
  • CPD Released: 10/19/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 10/19/2022
Start Activity


Target Audience and Goal Statement

This activity is intended for retina specialists, ophthalmologists, diabetologists/endocrinologists and other physicians with an interest in retinal diseases.

The goal of this activity is to disseminate data on emerging therapies in diabetic macular edema (DME) and highlight unmet medical needs from burden of disease and burden of treatment as seen from the perspectives of the patient and the clinician, respectively.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Disease burden on patients with DME
    • Undertreatment of DME
    • Emerging late-stage therapies in DME


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Jean-François Korobelnik, MD, PhD

    Professor of Ophthalmology
    Centre Hospitalier Universitaire de Bordeaux
    Bordeaux, France

    Disclosures

    Disclosure: Jean-François Korobelnik, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Allergan-AbbVie; Apellis; Bayer; Carl Zeiss Meditec; KangHong; Novartis; Novo Nordisk; Roche; Thea

  • Anat Loewenstein, MD, MHA

    Professor of Ophthalmology
    Deputy Dean
    Medical School at the Sackler
    Faculty of Medicine
    Tel Aviv University
    Tel Aviv, Israel

    Disclosures

    Disclosure: Anat Loewenstein, MD, MHA, has the following relevant financial relationships:
    Advisor or consultant for: Allergan; Bayer; Beyeonice Surgical; Novartis; Roche

  • David M. Brown, MD

    Clinical Professor of Ophthalmology
    Baylor College of Medicine
    Houston, Texas, United States

    Disclosures

    Disclosure: David M. Brown, MD, has the following relevant financial relationships:
    Advisor or consultant for: Adverum; Alexion; Annexon Biosciences; Apellis; Bayer; Boehringer Ingelheim; Celltrion; ChengduKanhong Biotechnology Co.; Clearside Biomedical; Dark Horse Consulting; Horizon Therapeutics; Jeffries; Kodiak Laboratories; Lineage; Novartis; Ocular Therapeutix; OPTOS; Regeneron; Retinai Medical; Senju; Stealth; THEA; Verseon; Wedbush
    Grants for clinical research from: Adverum; Aldeyra; Apellis; Bayer; BIRC; Boehringer Ingelheim; Clearside Biomedical; Cleveland Clinic Foundation; F. Hoffman-La Roche Limited; Gyroscope; Ionis; Iveris; Kodiak; Lowy Medical Research Institute; Lumithera; Nanoscope; NEI/NIH; NGM; Novartis; OIRRC OPTOS; Oxurion; Regeneron; RegenXBio; SanChunDang Pharm; Santen Senju Pharmaceutical

Editors

  • Pakinam Aboulsaoud, PharmD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

  • Yoji Yamaguchi, MA, ELS

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Yoji Yamaguchi, MA, ELS, has disclosed no relevant financial relationships.

Content Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Managing the Patient With DME: What's on the Horizon?

Authors: Jean-François Korobelnik, MD, PhD; Anat Loewenstein, MD, MHA; David M. Brown, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 10/19/2021

Valid for credit through: 10/19/2022

processing....

Contents of this CPD Activity

All sections of this activity are required for credit.

The Patient's Perspective

Dr Korobelnik examines the burden of DME treatment and management on patients.
Jean-François Korobelnik, MD, PhD

The Ophthalmologist's Perspective in Today's World in DME

Drs Korobelnik and Loewenstein discuss the challenges and unmet needs facing ophthalmologists treating patients with DME.
Jean-François Korobelnik, MD, PhD; Anat Loewenstein, MD, MHA

Emerging Late-Stage Therapies on the Horizon for DME

Drs Loewenstein and Brown look at the latest clinical trial data on emerging new treatments for DME.
Anat Loewenstein, MD, MHA; David M. Brown, MD

Educational Impact Challenge

The goal of this activity is to disseminate data on emerging therapies in diabetic macular edema (DME) and highlight unmet medical needs from burden of disease and burden of treatment as seen from the perspectives of the patient and the clinician, respectively.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.